Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant Chemotherapy With Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin in NSCLC IB, IIA, IIB, T3N1: a Randomized Phase II Study.

Next Previous
X
Search
Trial Profile

Adjuvant Chemotherapy With Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin in NSCLC IB, IIA, IIB, T3N1: a Randomized Phase II Study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin; Vinorelbine
  • Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms TREAT

    • Most Recent Events

    • 08 Sep 2014 Efficacy results presented at the 24th Annual Congress of the European Respiratory Society.
    • 14 Apr 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top